Abstracts tagged "Pediatric rheumatology"

Abstract Number: 1740 • ACR Convergence 2025
A New Link Between Calprotectin, Cholesterol Efflux Dysfunction, and Premature Atherosclerosis in Juvenile Dermatomyositis
Emily Chong¹, Kavya Sugur², Sophia Matossian¹, Katarina Kmetova³, Christine Goudsmit⁴, Jessica Turnier⁵ and Yu (Ray) Zuo¹, ¹University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Ann Arbor, MI, ³Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, ⁴University of Michigan, Ann Arbor, ⁵University of Michigan, Saline, MI
Background/Purpose: Adults with dermatomyositis face a well-established 2–3-fold increased risk of major adverse cardiovascular events, driven by systemic inflammation, endothelial dysfunction, and treatment-related metabolic complications.…
Abstract Number: 1301 • ACR Convergence 2025
Prevalence, Clinical and Genetic Risk Factors, and Time to Cataract Development in Childhood-onset Systemic Lupus Erythematosus
Sirikarn Tangcheewinsirikul¹, Zhaoyu Ding², Nicholas Chan³, Daniela Dominguez³, Andrea Knight⁴, Deborah Levy¹, Lawrence Ng⁵, Earl Silverman¹, Ruud Verstegen¹ and Linda Hiraki¹, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²SickKids Research Institute, Toronto, ON, Canada, ³The Hospital for Sick Children, Toronto, Canada, ⁴Hospital for Sick Children, Toronto, ON, Canada, ⁵The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: Cataracts are a significant ocular complication in childhood-onset systemic lupus erythematosus (cSLE). This study aimed to assess the prevalence, time to cataract development, and…
Abstract Number: 1285 • ACR Convergence 2025
Investigating the Relationship Between Brain Injury Markers and Brain Volume in Children with Systemic Lupus Erythematosus and Healthy Controls
Ganesh Ramanathan¹, Diana Valdes Cabrera², Oscar Mwizerwa³, Justine Ledochowski², Tala El Tal⁴, Sarah Mossad⁵, Ibrahim Mohamed¹, Joanna Law⁶, Lawrence Ng⁷, Paris Moaf², Asha Jeyanathan⁶, Adrienne Davis⁶, Ann Yeh⁶, Linda Hiraki², Deborah Levy², Zahi Touma⁸, Joan Wither⁹, Busisiwe Zapparoli¹⁰, Ashley Danguecan⁵ and Andrea Knight⁵, ¹The Hospital for Sick Children, Brampton, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada, ⁵Hospital for Sick Children, Toronto, ON, Canada, ⁶The Hospital for Sick Children, Toronto, Canada, ⁷The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, ⁸University of Toronto, Toronto, ON, Canada, ⁹University Health Network, Toronto, ON, Canada, ¹⁰The Hospital for Sick Children, Etobicoke, ON, Canada
Background/Purpose: Patients with childhood-onset systemic lupus erythematosus (cSLE) are at high risk for neuropsychiatric involvement as disease onset typically occurs during the critical period of…
Abstract Number: 0993 • ACR Convergence 2025
NOD2 mutations mediate IL-17 predisposition in patients with Blau syndrome
Leah Huey¹, Emily Vance², Bryce Binstadt³ and Ruth Napier², ¹Oregon Health & Science University, Denver, CO, ²University of Colorado Anschutz, Aurora, CO, ³University of Minnesota, Minneapolis, MN
Background/Purpose: Blau syndrome is a pediatric rheumatic disease characterized by dermatitis, arthritis, and uveitis. Blau syndrome is caused by inborn or de novo mutations in…
Abstract Number: 0412 • ACR Convergence 2025
The Association of Obesity with Juvenile Spondyloarthritis
Katelyn Baggett¹, Timothy Brandon² and Pamela Weiss³, ¹Johns Hopkins University, Newtown Square, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Childrens Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Childhood obesity is a global public health concern that impacts the health and wellbeing of all children and particularly negatively affects children living with…
Abstract Number: 0358 • ACR Convergence 2025
Different Perspectives between Physicians and Patients on Treatment Priorities and Challenges in Still’s Disease
Gisella Beatrice Beretta¹, Luciana Pereira², Greta Rogani³, Francesco Baldo⁴, Claudia Bracaglia⁵, Dirk Foell⁶, Marco Gattorno⁷, Marija Jelusic⁸, Sebastiaan Vastert³, Rashmi Sinha⁹ and Francesca Minoia¹⁰, ¹Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy, Milan, Italy, ²Systemic JIA Foundation, Cincinnati, ³University Medical Center Utrecht, Utrecht, Utrecht, Netherlands, ⁴ASST-Pini-CTO, Milano, Milan, Italy, ⁵IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Rome, Italy, ⁶University Hospital Muenster, Muenster, Germany, ⁷IRCCS G. Gaslini, Genova, Genoa, Italy, ⁸University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Zagreb, Croatia, ⁹Systemic JIA Foundation, Cincinnati, OH, ¹⁰Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Milan, Italy
Background/Purpose: Despite therapeutic advances, major concerns and disparities persist in the care of Still’s Disease (SD). Capturing both patient/caregiver and physician perspectives is essential to…
Abstract Number: 2181 • ACR Convergence 2025
A Pilot High-Fidelity Simulation for Pediatric Rheumatology Learners
John Bridges¹, Livie Timmerman² and Nicholas Rockwell³, ¹University of Alabama at Birmingham/Children's of Alabama, Birmingham, AL, ²University of Alabama at Birmingham, Gardendale, AL, ³University of Alabama at Birmingham, Birmingham
Background/Purpose: The ACGME’s core competencies for pediatric residency training include medical knowledge, patient care, and interpersonal communication skills. At our institution, residents only spend two…
Abstract Number: 2142 • ACR Convergence 2025
Multidisciplinary Rheumatology Transition Clinic for Young Adults Shows Improved Experience, Utilization, and Health Maintenance: A Mixed-Methods Evaluation
Hannah Concannon¹, Jasmine Oesch², Sara Mazzarelli², Anne Fields², Keisha-Gaye O'Garo² and Rebecca Sadun³, ¹Duke University School of Medicine, Chapel Hill, NC, ²Duke University School of Medicine, Durham, NC, ³Duke University, Durham, NC
Background/Purpose: The transition from pediatric to adult care can pose a challenge for patients with SLE and other rheumatic diseases. These patients often face preventable…
Abstract Number: 1826 • ACR Convergence 2025
Single Nuclei Multiome of JDM Muscle Biopsies Reveals Novel Upregulation of Inflammatory and Vascular Pathways
Shannon O'Connor, Casey Swoboda, Matthew Weirauch, Alexander Zygmunt, Douglas Millay and Leah Kottyan, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Juvenile dermatomyositis (JDM) is a multisystem vasculopathy and inflammatory myopathy characterized by proximal muscle weakness, distinct rash, and risk of long-term complications such as…
Abstract Number: 1741 • ACR Convergence 2025
Chronic JDM Plasma Proteomic Signature Reflects Inflammation from Immune and Tissue-resident Muscle and Skin
Marianne Kerski¹, Celine Berthier¹, Benjamin Klein¹, Li Chen², Christine Goudsmit², Sophia Matossian¹, Qinmengge Li³, Chioma Madubata⁴, Jessica Neely⁵, J. Michelle Kahlenberg¹ and Jessica Turnier⁶, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, ³University of Michigan, Ypsilanti, MI, ⁴UCSF, SF, CA, ⁵UCSF, San Francisco, CA, ⁶University of Michigan, Saline, MI
Background/Purpose: Juvenile dermatomyositis (JDM) and childhood-onset SLE (cSLE) are systemic autoimmune diseases characterized by overlapping yet distinct clinical manifestations and treatment responses. In this study,…
Abstract Number: 1300 • ACR Convergence 2025
International Assessment of cSLE Clinical Remission (cCR) Criteria in Childhood Lupus: Sensitivity Analyses from the UK JSLE Cohort and the CARRA Registry
Chandni Sarker¹, Jennifer Cooper², Emily Smitherman³, Flavia Alves¹, Alexandre Belot⁴, Michael Beresford⁵, Andreea Jorgensen¹, Eve Smith⁶, Laura Lewandowski⁷ and Rebecca Sadun⁸, ¹University of Liverpool, Liverpool, United Kingdom, ²University of Colorado/Children's Hospital Colorado, Aurora, CO, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Hospices Civils de Lyon, Collonges au mont d'or, France, ⁵Alder Hey Children's NHS Foundation Trust Hospital, Department of Women's & Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom, ⁶University of Glasgow, Glasgow, United Kingdom, ⁷NIAMS, NIH, Bethesda, MD, ⁸Duke University, Durham, NC
Background/Purpose: Consensus-derived treat-to-target (T2T) goals for childhood-onset SLE (cSLE), including clinical remission on low dose steroids (cCR), have been endorsed by the Paediatric Rheumatology European…
Abstract Number: 1283 • ACR Convergence 2025
Impact of Guideline Concordant Care of Renal Outcomes in Childhood-Onset Lupus Nephritis
Alisha Akinsete¹, Orysya Soroka², Mangala Rajan², Karen Onel³, Monika Safford² and Iris Navarro-Millan⁴, ¹Weill Cornell Medical Center, New York, NY, ²Weill Cornell Medicine, New York, ³HSS, New York, NY, ⁴Weill Cornell Medicine, Hospital for Special Surgery, Poughkeepsie, NY
Background/Purpose: End-stage renal disease (ESRD) is a serious complication of lupus nephritis (LN), yet the effect of guideline-concordant care on this outcome is unclear. Despite…
Abstract Number: 0875 • ACR Convergence 2025
Efficacy and Safety of Icotrokinra, a Novel Targeted Oral Peptide (IL-23R-Inhibitor), in Adolescents With Moderate-to-Severe Plaque Psoriasis: Subgroup Analyses From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (ICONIC-LEAD)
Lawrence Eichenfield¹, Ricardo Galimberti², Adelaide Hebert³, Wen-Hui Wang⁴, Jennifer Soung⁵, Nina Magnolo⁶, John Browning⁷, Angela Moore⁸, Mark Lebwohl⁹, Dagmar Wilsmann-Theis¹⁰, Joseph F Merola¹¹, Georgios Kokolakis¹², Dariusch Mortazawi¹³, Parbeer Grewal¹⁴, Megan Miller¹⁵, Joseph Cafone¹⁶, Shu Li¹⁷, Gigi Jiang¹⁷, Fabio Nunes¹⁷, Cynthia DeKlotz¹⁸ and Amy Paller¹⁹, ¹University of California, San Diego School of Medicine, La Jolla, CA, USA, La Jolla, CA, ²Hosp Italiano de Buenos Aires, Buenos Aires, Argentina, Buenos Aires, Argentina, ³University of Texas Medical School-Houston, Bellaire, TX, USA, Bellaire, TX, ⁴Peking University Third Hospital, Haidian District, Beijing, China, Beijing, China (People's Republic), ⁵Southern California Dermatology, Inc, Santa Ana, CA, USA, Santa Ana, ⁶University Hospital Muenster, Muenster, Germany, Muenster, Germany, ⁷Methodist Children's Hospital, San Antonio, TX, USA, San Antonio, TX, ⁸Baylor University Medical Center, Dallas, TX, USA, Dallas, TX, ⁹Icahn School of Medicine at Mount Sinai, New York, NY, ¹⁰University Hospital Bonn, Center for Skin Diseases, Bonn, Germany, Bonn, Germany, ¹¹Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ¹²Charité-Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany, ¹³Clinical Research Center, Remscheid, Germany, Remscheid, Germany, ¹⁴University of Alberta, Edmonton, Alberta, Canada, Edmonton, AB, Canada, ¹⁵Johnson & Johnson, San Diego, CA, USA, San Diego, CA,, CA, ¹⁶Johnson & Johnson, San Diego, CA, USA, San Diego, CA, CA, ¹⁷Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ¹⁸Johnson & Johnson, San Diego, CA, USA, San Diego, CA, ¹⁹Northwestern University Feinberg School of Medicine, Chicago, IL, USA, Chicago, IL
Background/Purpose: Icotrokinra (ICO), a novel targeted oral peptide, binds the interleukin (IL)-23 receptor to inhibit IL-23 signaling. ICONIC-LEAD (NCT06095115) is the first Phase 3 study…
Abstract Number: 0407 • ACR Convergence 2025
The SOS project: to Switch Or to Swap After Adalimumab failure for the management of childhood non-infectious uveitis in an international cohort
Ilaria Maccora¹, Margaret Chang², Sheila Angeles-Han³, Andrea Taddio⁴, Lampros Fotis⁵, Cinzia de Libero⁶, Madison Mangin⁷, Alexandra Duell⁸, Marco Gabrielli⁹, Kyveli Chiotopoulou⁵, Lillian Sutton¹⁰, Virginia Miraldi Utz⁸ and Gabriele Simonini¹¹, ¹Rheumatology Unit, ERN ReCoNNET Center, Meyer Children's Hospital IRCCS, Florence, Italy, Firenze, Florence, Italy, ²Boston Children's Hospital, Boston, MA, ³Cincinnati Children's Hospital, Cincinnati, OH, ⁴Insitute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy, ⁵Division of Pediatric Rheumatology, Department of Pediatrics, ATTIKON General Hospital, National and Kapodistrian University of Athens, Greece, Athene, Greece, ⁶Ophthalmology Unit, Meyer Children's Hospital IRCCS, Florence, Italy, Florence, Italy, ⁷Boston Children's Hospital, St Simons Island, GA, ⁸Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹University of Trieste, Trieste, Italy, Trieste, Italy, ¹⁰Division of Immunology, Boston Children’s Hospital, Boston, MA, USA, Boston, ¹¹Rheumatology Unit, ERN-ReCONNET center, Meyer Children's Hospital IRCCS, Firenze, Firenze, Italy
Background/Purpose: Childhood chronic non-infectious uveitis (cNIU) is a sight-threatening condition that can lead to blindness if not appropriately treated. cNIU is typically associated with Juvenile…
Abstract Number: 0302 • ACR Convergence 2025
Urine Kynurenine Pathway Biomarkers Correlate with Disease Activity and Damage Core Set Measures in JDM
Shannon O'Connor¹, Hermine Brunner¹, Josh Gunn², Payam Farhadi³, Carley Phillips⁴, Lisa Rider⁵, Alexei Grom¹ and Sheila Angeles-Han⁶, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Ethos R&D, Newport, KY, ³National Institutes of Health/National Institute of Environmental Health Sciences, Bethesda, MD, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, ⁵National Institute of Environmental Health Sciences/National Institutes of Health, Environmental Autoimmunity Group, Bethesda, MD, ⁶Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Juvenile dermatomyositis (JDM) is an autoimmune vasculopathy affecting muscle, skin, and vasculature. Core set measures (CSM) assess disease activity and damage, and guide treatment.…

« Previous Page
1
…
8
9
10
11
12
…
62
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].